MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression

Oncotarget

Volumn 7, Issue 18, 2016, Pages 26516-26534

  Zhang, Jing ^a   Liu, Lei ^b   Sun, Yunyan ^a   Xiang, Jiandong ^a   Zhou, Dongmei ^a   Wang, Li ^a   Xu, Huali ^a   Yang, Xiaoming ^a   Du, Na ^a   Zhang, Meng ^c   Yan, Qin ^a   Xi, Xiaowei ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Chemoresistance; DAPK2; Epithelial ovarian cancer; MiR 520g; Progression

Indexed keywords

CASPASE 3; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DEATH ASSOCIATED PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE 2; MICRORNA; MICRORNA 520G; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; DAPK2 PROTEIN, HUMAN; MIRN520 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME BINDING; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVERALL SURVIVAL; UPREGULATION; AGED; ANIMAL; BIOSYNTHESIS; CELL MOTION; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; NEOPLASM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE; TUMOR INVASION; XENOGRAFT;

ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DEATH-ASSOCIATED PROTEIN KINASES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS;

EID: 84967333776     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8530     Document Type: Article

References (44)

1. Chien JR, Aletti G, Bell DA, Keeney GL, Shridhar V, Hartmann LC. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J Cell Biochem. 2007; 102:1117-1129.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
3. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009; 374:1371-1382.
4. Bast RC, Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9:415-428.
5. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007; 25:517-525.
6. Nagaraj AB, Joseph P, DiFeo A. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomark Med. 2015; 9:241-257.
7. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol. 2010; 42:1262-1272.
8. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Menard S, Croce CM. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007; 67:8699-8707.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
10. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6:857-866.
11. Fang L, Li H, Wang L, Hu J, Jin T, Wang J, Yang BB. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014; 5:2974-2987. doi: 10.18632/oncotarget.1614.
12. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007; 302:1-12.
13. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011; 140:1618-1628.
14. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009; 11:27-45.
15. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Guckel B, Fehm T, Schneeweiss A, Sahin O, Wiemann S, Tschulena U. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene. 2012; 31:4150-4163.
16. Kan H, Guo W, Huang Y, Liu D. MicroRNA-520g induces epithelial-mesenchymal transition and promotes metastasis of hepatocellular carcinoma by targeting SMAD7. FEBS Lett. 2015; 589:102-109.
17. Zhang Y, Geng L, Talmon G, Wang J. MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem. 2015; 290:6215-6225.
18. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev. 1995; 9:15-30.
19. Bai T, Tanaka T, Yukawa K, Maeda M, Umesaki N. Reduced expression of death-associated protein kinase in human uterine and ovarian carcinoma cells. Oncol Rep. 2004; 11:661-665.
20. Chen CH, Wang WJ, Kuo JC, Tsai HC, Lin JR, Chang ZF, Chen RH. Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO J. 2005; 24:294-304.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
22. Hsu TS, Chen C, Lee PT, Chiu SJ, Liu HF, Tsai CC, Chao JI. 7-Chloro-6-piperidin-1-yl-quinoline-5, 8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway. Cancer Chemother Pharmacol. 2008; 62:799-808.
23. Ber Y, Shiloh R, Gilad Y, Degani N, Bialik S, Kimchi A. DAPK2 is a novel regulator of mTORC1 activity and autophagy. Cell Death Differ. 2015; 22:465-475.
24. Finlay D, Healy V, Furlong F, O'Connell FC, Keon NK, Martin F. MAP kinase pathway signalling is essential for extracellular matrix determined mammary epithelial cell survival. Cell Death Differ. 2000; 7:302-313.
25. Kamal M, Pawlak A, BenMohamed F, Valanciute A, Dahan K, Candelier M, Lang P, Guellaen G, Sahali D. C-mip interacts with the p85 subunit of PI3kinase and exerts a dual effect on ERK signaling via the recruitment of Dip1 and DAP kinase. FEBS Lett. 2010; 584:500-506.
26. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Fuso Nerini I, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, Milani R, Torri V, Romualdi C, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer. 2013; 49:520-530.
27. Zhang P, Shi B, Zhou M, Jiang H, Zhang H, Pan X, Gao H, Sun H, Li Z. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis. 2014; 5: 991-999.
28. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC, Pellegrini P, Califano D, Pignata S, Losito S, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A. 2013; 110:9845-9850.
29. Cai J, Yang C, Yang Q, Ding H, Jia J, Guo J, Wang J, Wang Z. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis. 2013; 2 :75-83.
30. Liu L, Guo J, Yu L, Cai J, Gui T, Tang H, Song L, Wang J, Han F, Yang C, Chen C, Marks A, Wang Z. miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biol. 2014; 35:12619-12626.
31. Lu L, Katsaros D, Risch HA, Canuto EM, Biglia N, Yu H. MicroRNA let-7a Modifies the Effect of Self-Renewal Gene HIWI on Patient Survival of Epithelial Ovarian Cancer. Mol Carcinog. 2016; 55:357-65.
32. Yan DW, Fan JW, Yu ZH, Li MX, Wen YG, Li DW, Zhou CZ, Wang XL, Wang Q, Tang HM, Peng ZH. Downregulation of metallothionein 1F, a putative oncosuppressor, by loss of heterozygosity in colon cancer tissue. Biochim Biophys Acta. 2012; 1822:918-926.
33. Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene. 2005; 24:2909-2915.
34. Tsai EM, Wang YS, Lin CS, Lin WY, Hsi E, Wu MT, Juo SH. A microRNA-520mirSNP at the MMP2 gene influences susceptibility to endometriosis in Chinese women. J Hum Genet. 2013; 58:202-209.
35. Addison JB, Koontz C, Fugett JH, Creighton CJ, Chen D, Farrugia MK, Padon RR, Voronkova MA, McLaughlin SL, Livengood RH, Lin CC, Ruppert JM, Pugacheva EN, et al. KAP1 promotes proliferation and metastatic progression of breast cancer cells. Cancer Res. 2015; 75:344-355.
36. Zhou HC, Fang JH, Luo X, Zhang L, Yang J, Zhang C, Zhuang SM. Downregulation of microRNA-100 enhances the ICMT-Rac1 signaling and promotes metastasis of hepatocellular carcinoma cells. Oncotarget. 2014; 5:12177-12188. doi: 10.18632/oncotarget.2601.
37. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013; 23:186-199.
38. Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat F, Paone A, Cascione L, Sumani KM, et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell. 2014; 25:469-483.
39. Su CM, Wang MY, Hong CC, Chen HA, Su YH, Wu CH, Huang MT, Chang YW, Jiang SS, Sung SY, Chang JY, Chen LT, Chen PS, et al. miR-520h is crucial for DAPK2 regulation and breast cancer progression. Oncogene. 2016; 35:1134-42.
40. Schlegel CR, Georgiou ML, Misterek MB, Stocker S, Chater ER, Munro CE, Pardo OE, Seckl MJ, Costa-Pereira AP. DAPK2 regulates oxidative stress in cancer cells by preserving mitochondrial function. Cell Death Dis. 2015; 6:e1671.
41. Soussi H, Reggio S, Alili R, Prado C, Mutel S, Pini M, Rouault C, Clement K, Dugail I. DAPK2down-regulation associates with attenuated adipocyte autophagic clearance in human obesity. Diabetes. 2015; 64 :3452-63 .
42. Li L, Tanaka T, Yukawa K, Akira S, Umesaki N. Irinotecan-induced ovarian follicular apoptosis is attenuated by deleting the kinase domain of death-associated protein kinase. Int J Oncol. 2009; 34:905-914.
43. Wang L, Mao Y, Du G, He C, Han S. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer. Tumour Biol. 2015;36 :2465-72.
44. Zhao S, Jiang T, Tang H, Cui F, Liu C, Guo F, Lu H, Xue Y, Jiang W, Peng Z, Yan D. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy. J Gastroenterol Hepatol. 2015; 30:680-688.